المؤلفون: Draghiciu, Oana, Lubbers, Joyce, Nijman, Hans W., Daemen, Toos

المصدر: Draghiciu , O , Lubbers , J , Nijman , H W & Daemen , T 2015 , ' Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy ' , OncoImmunology , vol. 4 , no. 1 , e954829 . https://doi.org/10.4161/21624011.2014.954829Test

مصطلحات موضوعية: 5-Fluorouracil, all-trans retinoic acid, bisphosphonates, gemcitabine, immune suppressive mechanisms, myeloid-derived suppressor cells, sunitinib therapeutic vaccination, TRANS-RETINOIC ACID, TUMOR-BEARING MICE, CD8(+) T-CELLS, ANTITUMOR IMMUNITY, CANCER-PATIENTS, CARCINOMA PATIENTS, IMMUNOSUPPRESSIVE ACTIVITY, ESTABLISHED TUMORS, WITHANIA-SOMNIFERA, IN-VIVO

العلاقة: https://research.rug.nl/en/publications/05e3ae45-a2ac-425b-889e-e4aced877bdfTest

الإتاحة: https://doi.org/10.4161/21624011.2014.954829Test
https://hdl.handle.net/11370/05e3ae45-a2ac-425b-889e-e4aced877bdfTest
https://research.rug.nl/en/publications/05e3ae45-a2ac-425b-889e-e4aced877bdfTest

المصدر: OncoImmunology. 4(1)

مصطلحات موضوعية: TUMOR-BEARING MICE, immune suppressive mechanisms, 5-Fluorouracil, sunitinib therapeutic vaccination, IMMUNOSUPPRESSIVE ACTIVITY, gemcitabine, CANCER-PATIENTS, CD8(+) T-CELLS, myeloid-derived suppressor cells, all-trans retinoic acid, CARCINOMA PATIENTS, TRANS-RETINOIC ACID, ANTITUMOR IMMUNITY, ESTABLISHED TUMORS, bisphosphonates, WITHANIA-SOMNIFERA, IN-VIVO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dris___01423::95061bce256191719f632ac3d8b4d225Test
https://doi.org/10.4161/21624011.2014.954829Test

المؤلفون: Toos Daemen, Joyce M Lubbers, Hans W. Nijman, Oana Draghiciu

المصدر: Oncoimmunology

مصطلحات موضوعية: CD62L, L-selectin, TUMOR-BEARING MICE, MDSCs, myeloid-derived suppressor cells, STAT3, signal transducer and activator of transcription 3, medicine.medical_treatment, ARG1, arginase-1, ATRA, all-trans retinoic acid, PDE-5, phosphodiesterase type 5, Review, IMCs, immature myeloid cells, HNSCC, head and neck squamous cell carcinoma, law.invention, APCs, antigen presenting cells, CARCINOMA PATIENTS, iNOS2, inducible nitric oxid synthase 2, law, GM-CSF/CSF2, granulocyte monocyte colony stimulating factor, ANTITUMOR IMMUNITY, GSH, glutathione, TGFβ, transforming growth factor β, Immunology and Allergy, Cytotoxic T cell, JAK2, Janus kinase 2, IN-VIVO, TCR, T cell receptor, gemcitabine, IL-1β, interleukin 1 β, NSAID, nonsteroidal anti-inflammatory drugs, c-kit, Mast/stem cell growth factor receptor, all-trans retinoic acid, TNFα, tumor necrosis factor α, IL-6, interleukin 6, mRCC, metastatic renal cell carcinoma, CCL2, chemokine (C-C motif) ligand 2, Oncology, VEGFR, vascular endothelial growth factor receptor, Tregs, regulatory T cells, CDDO-Me, bardoxolone methyl, ESTABLISHED TUMORS, DCs, dendritic cells, WITHANIA-SOMNIFERA, medicine.drug, MMPs, metalloproteinases (e.g., MMP9), CTLs, cytotoxic T lymphocytes, ERK1/2, extracellular signal-regulated kinases, FoxP3, forkhead box P3, 5-Fluorouracil, Immunology, sunitinib therapeutic vaccination, IFNγ, interferon γ, CANCER-PATIENTS, CD8(+) T-CELLS, Biology, ODN, oligodeoxynucleotides, RNS, reactive nitrogen species, ROS, reactive oxygen species, In vivo, IL-4, interleukin 4, TAMs, tumor-associated macrophages, medicine, PGE2, prostaglandin E2, WA, withaferin A, GITR, anti-glucocorticoid tumor necrosis factor receptor, bisphosphonates, CXCL15, chemokine (C-X-C motif) ligand 15, Flt3, Fms-like tyrosine kinase 3, WRE, Withaferin somnifera, NO, nitric oxide, immune suppressive mechanisms, HLA, human leukocyte antigen, SCF, stem cell factor, IMMUNOSUPPRESSIVE ACTIVITY, HSCs, hematopoietic stem cells, Cancer, COX2, cyclooxygenase 2, Immunotherapy, NADPH, nicotinamide adenine dinucleotide phosphate-oxidase NK cells, natural killer cells, medicine.disease, myeloid-derived suppressor cells, HPV-16, human papillomavirus 16, ADAM17, metalloproteinase domain-containing protein 17, Gemcitabine, Blockade, TRANS-RETINOIC ACID, NOHA, N-hydroxy-L-Arginine, NAC, N-acetyl cysteine, Myeloid-derived Suppressor Cell, Suppressor, CXCL12, chemokine (C-X-C motif) ligand 12, 5-FU, 5-fluorouracil, HIF-1α, hypoxia inducible factor 1α, IL-10, interleukin 10, Myd88, myeloid differentiation primary response protein 88, ICT, 3, 5, 7-trihydroxy-4′-emthoxy-8-(3-hydroxy-3-methylbutyl)-flavone, IL-13, interleukin 13

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d066a21e4c242e158360b8a1aa115a0Test
https://pubmed.ncbi.nlm.nih.gov/25949858Test